• head_banner_01

MOTS-C

ʻO ka wehewehe pōkole:

Hoʻokumu ʻia ka MOTS-C API ma lalo o nā kūlana GMP-like koʻikoʻi me ka hoʻohana ʻana i ka ʻenehana solid phase peptide synthesis (SPPS) e hōʻoia i kona kiʻekiʻe kiʻekiʻe, kiʻekiʻe maʻemaʻe a me ke kūpaʻa kiʻekiʻe no ka noiʻi a me ka hoʻohana therapeutic.
Nā hiʻohiʻona huahana:

Maʻemaʻe ≥ 99% (hōʻoia ʻia e HPLC a me LC-MS),
ʻO ka endotoxin haʻahaʻa a me ke koena o ka solvent content,
Hana ʻia e like me ICH Q7 a me GMP-like protocols,
Hiki ke hoʻokō i ka hana nui, mai ka milligram-level R&D pūʻulu a hiki i ka gram-level a me ka kilokani-level lako kalepa.


Huahana Huahana

Huahana Huahana

MOTS-C API

MOTS-C(Mitochondrial Open Reading Frame o ka 12S rRNA Type-c) he 16-amino acid.peptide i loaʻa mai i ka mitochondria (MDP)hoʻopili ʻia e ka genome mitochondrial. ʻAʻole like me nā peptides nuclear-encoded kuʻuna, MOTS-c mai ka 12S rRNA māhele o ka mitochondrial DNA a he hana koʻikoʻi i loko.ka hoʻoponopono ʻana i ka metabolism cellular, ka pane ʻana i ke kaumaha, a me ka ʻike insulin.

Ma ke ʻano he peptide therapeutic hou,MOTS-c APIua loaʻa i ka hoihoi nui ma nā kahua onā maʻi metabolic, ka ʻelemakule, ka physiology hoʻoikaika kino, a me ka lāʻau lapaʻau mitochondrial. Aia ka peptide i kēia manawa ma lalo o ka hoʻokolokolo preclinical ikaika a manaʻo ʻia he moho hoʻohiki nonā lāʻau lapaʻau peptide e hiki mai anake kuhikuhi nei i ke olakino metabolic a me ke ola lōʻihi.


Mechanism of Action

Hoʻohana ʻo MOTS-c i kāna mau hopena ma omitochondrial-nuclear cross-talk—he hana e kamaʻilio ai ka mitochondria me ka nucleus e mālama i ka homeostasis cellular. Hoʻololi ʻia ka peptide mai ka mitochondria i ka nucleus i ka pane ʻana i ke koʻikoʻi metabolic, kahi e hana ai ma ke ʻano hemea hoʻoponopono metabolicma ka hoʻololi ʻana i ka hōʻike gene.

ʻO nā mīkini olaola koʻikoʻi nā:

  • Ka ho'ā 'ana o AMPK (AMP-activated protein kinase):Hoʻoulu ʻo MOTS-c i ka AMPK, kahi mea ʻike ikehu waena, hoʻolahaka lawe ʻana i ka glucose, ka hoʻohemo ʻana i ka waikawa momona, a me ka biogenesis mitochondrial.

  • Hoʻonui i ka naʻau o ka insulin:Hoʻonui ka MOTS-c i ka pane ʻana o ka insulin i ka ʻiʻo a me ka ʻiʻo adipose, hoʻomaikaʻika homeostasis glucose.

  • Hoʻopau i ke kaumaha oxidative a me ka mumū:Ma ka hoʻololi ʻana i ke kaulike redox cellular a me nā ala hōʻailona inflammatory.

  • Hoʻoponopono i ka hana mitochondrial a me ka biogenesis:Kākoʻo i ke olakino mitochondrial, ʻoi aku ma lalo o ke kaumaha a i ʻole nā ​​kūlana ʻelemakule.


Noiʻi Therapeutic a me nā hopena olaola

Ua hōʻike nā haʻawina preclinical i kahi ākea o ka hopena physiological a me ka therapeutic o MOTS-c i loko o ka vitro a me nā hiʻohiʻona holoholona:

1. ʻO nā maʻi maʻi metabolic (Obesity, Type 2 Diabetes, Insulin Resistance)

  • Hoʻomaikaʻi i ka ʻae ʻana i ka glucose a hoʻohaʻahaʻa i nā pae glucose koko

  • Hoʻonuiʻike i ka insulinme ka hoʻonui ʻole i ka pae o ka insulin

  • Hoʻolahakaumaha kaumaha a me ka momona oxidationi nā ʻiole momona i hoʻokomo ʻia i ka ʻai

2. Anti-Aging and Longevity

  • Ke emi nei nā pae MOTS-c me ka makahiki, a ua hōʻike ʻia ka hoʻohui ʻana i nā ʻiole kahikohoʻonui i ka hiki kino, hoʻonui i ka hana mitochondrial, ahoʻolohi i ka emi ʻana o ka makahiki.

  • Hoʻomaikaʻi i ka hana hoʻoikaika kino ahoʻomanawanui ʻiʻoma o ka hoʻonui ʻana i ka metabolism oxidative.

3. ʻO ka pale ʻana i ka Mitochondrial a me ka Cellular Stress Protection

  • Hoʻonuike ola kino ma lalo o ka metabolic a i ʻole ke koʻikoʻi oxidativekūlana.

  • Hoʻonui i ka hōʻike ʻana o nā genes pili mehoʻoponopono pūnaewele a me ka autophagy.

4. ʻO ka maʻi cardiovascular a me ka Neuroprotective Potential

  • Hōʻike nā haʻawina mua e hiki ke pale ʻo MOTS-cnā pūnaewele endothelial vasculara hoʻemi i nā hōʻailona koʻikoʻi o ka naʻau.

  • Hiki i nā waiwai neuroprotective ma onā ala anti-inflammatory a me nā antioxidativeaia ma ka hookolokolo ana.


Hana ʻia API a me nā ʻano maikaʻi

At Pūʻulu Gentolex, ko makouMOTS-c APIhana ʻia me ka hoʻohana ʻanaka hana peptide synthesis (SPPS)ma lalo o nā kūlana GMP-like koʻikoʻi, e hōʻoia ana i ke kūlana kiʻekiʻe, ka maʻemaʻe, a me ke kūpaʻa no ka noiʻi a me ka hoʻohana therapeutic.

Nā hiʻohiʻona huahana:

  • Maʻemaʻe ≥99% (HPLC a me LC-MS i hōʻoia ʻia)

  • ʻO ka endotoxin haʻahaʻa a me ke koena o ka solvent maʻiʻo

  • Hana ʻia ma lalo o ICH Q7 a me GMP-like protocols

Loaʻa ka hana hiki ke hoʻonui ʻia, maimilligram R&D pūʻulu i ka gram- a me kilo-level lako kalepa.


  • Mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou